A Phase 2b, Multicenter, Randomized, Open-label, Two-Arm Study to Evaluate the Clinical Efficacy and Safety of OHB-607 Compared to Standard Neonatal Care for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease of Prematurity

The purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.

Start Date09 May 2019

Sponsor / Collaborator

Oak Hill Bio Corp.

NCT01096784 / CompletedPhase 2

Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study

To compare the severity of retinopathy of prematurity (ROP) among treated infants with an untreated control population, matched for gestational age at birth while confirming the dose of rhIGF-1/rhIGFBP-3 is safe and efficacious.

Start Date18 Jun 2010

Sponsor / Collaborator

Shire Plc

NCT00577577 / CompletedPhase 2

A Placebo Controlled, Randomized, Double-Blind Phase II Clinical Trial to Evaluate Tolerability, Safety and Efficacy Endpoints After Administration of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) for 24 Weeks in Adults With Myotonic Dystrophy Type 1

To investigate the effects of rhIGF-I/rhIGFBP-3 treatment for 24 weeks on endurance, ambulation, cognitive functioning, insulin resistance, lipid levels, muscle function and strength, pain, gastrointestinal functioning, and quality of life endpoints in DM1 patients

Start Date01 Dec 2007

Sponsor / Collaborator

Insmed, Inc.

[+1]

100 Clinical Results associated with Mecasermin Rinfabate

100 Translational Medicine associated with Mecasermin Rinfabate

100 Patents (Medical) associated with Mecasermin Rinfabate

352

Literatures (Medical) associated with Mecasermin Rinfabate

01 Aug 2023·Advanced materials (Deerfield Beach, Fla.)

Mimosa-Inspired Stimuli-Responsive Curling Bioadhesive Tape Promotes Peripheral Nerve Regeneration.

Article

Author: Jiang, Bao-Guo ; Zhang, Peixun ; Wen, Yongqiang ; Huang, Zhe ; Zhang, Meng ; Gu, Zhen ; Zhang, Fengshi ; An, Heng

Trauma often results in peripheral nerve injuries (PNIs). These injuries are particularly challenging therapeutically because of variable nerve diameters, slow axonal regeneration, infection of severed ends, fragility of the nerve tissue, and the intricacy of surgical intervention. Surgical suturing is likely to cause additional damage to peripheral nerves. Therefore, an ideal nerve scaffold should possess good biocompatibility, diameter adaptability, and a stable biological interface for seamless biointegration with tissues. Inspired by the curl of Mimosa pudica, this study aimed to design and develop a diameter-adaptable, suture-free, stimulated curling bioadhesive tape (SCT) hydrogel for repairing PNI. The hydrogel is fabricated from chitosan and acrylic acid-N-hydroxysuccinimide lipid via gradient crosslinking using glutaraldehyde. It closely matches the nerves of different individuals and regions, thereby providing a bionic scaffold for axonal regeneration. In addition, this hydrogel rapidly absorbs tissue fluid from the nerve surface achieving durable wet-interface adhesion. Furthermore, the chitosan-based SCT hydrogel loaded with insulin-like growth factor-I effectively promotes peripheral nerve regeneration with excellent bioactivity. This procedure for peripheral nerve injury repair using the SCT hydrogel is simple and reduces the difficulty and duration of surgery, thereby advancing adaptive biointerfaces and reliable materials for nerve repair.

01 Jan 2023·Animal science journal = Nihon chikusan Gakkaiho

Effects of low‐protein diet and feed restriction on mRNA expression of cationic amino acid transporters in porcine skeletal muscles

Article

Author: Katsumata, Masaya ; Nakashima, Kazuki ; Ishida, Aiko ; Ashihara, Akane

Abstract:

We investigated the effects of a low‐protein diet and feed restriction on the mRNA expression of cationic amino acid transporters (CATs) in the longissimus dorsi (LD), rhomboideus (RH), and biceps femoris (BF) muscles of pigs. Eighteen piglets were divided into three groups: a control (CP21%), low‐protein diet (LP, CP16%), and feed‐restricted diet (FR, CP21%, 76% feed intake of control pigs) groups. The expression levels of CAT‐1 in the LD and BF muscles of LP pigs were higher than that of control pigs, whereas that of FR pigs showed no difference. The CAT‐2A expression levels in the RH muscle of FR pigs were higher than that of control pigs. The free lysine concentrations in all muscles of LP and FR pigs were lower than that of control pigs. To examine the factors that affect CATs mRNA expression, we evaluated the effects of lysine, arginine, insulin‐like growth factor‐I, and dexamethasone on the expression of CATs in C2C12 myotubes. CAT‐1 expression levels increased in lysine and/or arginine deprivation. We show that CAT‐1 and CAT‐2A expression levels in skeletal muscles differ in response to dietary treatments and CAT‐1 expression in skeletal muscles appears to increase in response to low free lysine concentrations.

01 May 2022·Journal of pharmaceutical sciencesQ3 · MEDICINE

Development of Protein-Specific Analytical Methodologies to Evaluate Compatibility of Recombinant Human (rh)IGF-1/rhIGFBP-3 with Intravenous Medications Co-Administered to Neonates

Q3 · MEDICINE

Article

Author: Qu, Wanlu ; McPherson, Christopher ; Chadwick, Jennifer S ; Barton, Norman ; Salinas, Paul A ; Turner, Mark ; Salamat-Miller, Nazila ; Wang, Dongdong

The protein complex of recombinant human insulin-like growth factor-1 and insulin‑like growth factor binding protein‑3 (rhIGF-1/rhIGFBP-3; mecasermin rinfabate), is an investigational product for the prevention of complications of prematurity. Delivery of rhIGF-1/rhIGFBP-3 is by continuous central line intravenous infusion in preterm infants until endogenous IGF-1 production begins. Protein-specific analytical methodologies were developed to evaluate the compatibility of rhIGF-1/rhIGFBP-3 at low protein concentrations (∼2.5-10 μg/mL) expected when co-administered with other required medications in the NICU. Highly sensitive detection of the biologic potential degradants (fragments) and/or molecular modifications (oxidized species, aggregates) required the use of reversed-phase high-performance liquid chromatography and size-exclusion ultra-performance liquid chromatography coupled with mass spectrometric detection. We report on the quantification of rhIGF-1/rhIGFBP-3, its components and degradants, to a limit of quantitation of 3.1 μg/mL upon mixing with 24 commonly administered neonatal medications. Methods developed for the rhIGF-1/rhIGFBP-3 admixtures, optimized in studies with furosemide, caffeine citrate and ampicillin, demonstrated good reproducibility, linearity, and limit of detection/quantitation. Using these methods, no increase in degradation of rhIGF-1/rhIGFBP-3 components and no increase in oxidation or aggregation level was observed with caffeine citrate, while admixtures of rhIGF-1/rhIGFBP-3 with ampicillin yielded lower mass recovery of rhIGF-1/rhIGFBP-3 components, which likely resulted from adduct formation. Furosemide was found to be physically incompatible with rhIGF-1/rhIGFBP-3. Our findings support the use of these methodologies for detection of protein modifications under various clinical administration conditions, and additionally supplement physical compatibility data studies of ultra-low concentrations of rhIGF-1/rhIGFBP-3 post co-administration to preterm infants with other medications (manuscript in-preparation).

News (Medical) associated with Mecasermin Rinfabate

17 May 2024

·www.prnewswire.com

Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease in Premature Infants

Design of the multi-center study is based on Phase 2a clinical data, which showed a decrease in the occurrence of severe bronchopulmonary dysplasia (BPD), a condition for which there are no approved therapies. OHB-607 has the potential to be the first innovative respiratory therapeutic advance for extremely preterm neonates in over thirty years. Oak Hill Bio and Chiesi Group are collaborating to develop OHB-607 under a license and development agreement. CARY, N.C., May 17, 2024 /PRNewswire/ -- Oak Hill Bio, a clinical-stage neonatology and rare disease therapeutics company, and Chiesi, an international, research-focused biopharmaceutical group (Chiesi Group), announced that the first patient has been enrolled in a resumed Phase 2b clinical study to assess the efficacy and safety of OHB-607, an investigational drug candidate being developed to treat complications of extremely premature birth, including bronchopulmonary dysplasia (BPD), a serious condition for which there are no approved therapies. "As a neonatologist, I'm thrilled that we have restarted this groundbreaking clinical trial previously paused during the out-licensing process to Oak Hill Bio. OHB-607 can potentially improving the outcomes for infants born extremely premature," said Victoria Niklas, Chief Medical Officer at Oak Hill Bio. "At Oak Hill Bio, we are committed to advancing the field of neonatology and delivering the best possible care and outcomes to patients together with our partners at Chiesi." Diego Ardigò, Global research & Development Head at Chiesi Group said "Within the fragility of extreme prematurity lies a pressing need for action. With OHB-607, there is a chance to provide the babies with what they lack due to their immaturity. Addressing the medical needs of these infants goes beyond scientific inquiry; it's a moral imperative to safeguard their well-being." About the Phase 2b Study The Phase 2b clinical study is a multicenter, randomized, open-label, two-arm study designed to evaluate the efficacy and safety of OHB-607 compared to standard neonatal care for preventing BPD and other complications of prematurity among infants born extremely premature (between 23 and 28 weeks of gestation). The study will open at multiple centers across the US and shortly extend to Japan and Europe. It is designed to enroll at least 338 infants. OHB-607 will be administered by continuous intravenous infusion from 24 hours after birth until 30 weeks postmenstrual age. All infants will simultaneously receive standard neonatal care based on the individual infant's condition and local guidelines. The primary endpoint of the study is the reduction in the incidence of severe BPD or death by 36 weeks postmenstrual age compared to extremely premature infants receiving standard neonatal care alone. The study will also evaluate the impact of OHB-607 on weaning from respiratory technology support through 12 months corrected age as a longer-term respiratory outcome measure, the impact on neurodevelopment, and the incidence of other complications of prematurity, including intraventricular hemorrhage and retinopathy of prematurity. The study will utilize a modified National Institute of Child Health and Human Development (NICHD) score to define BPD severity grading, allowing the comparison of infants with the most severe form of the disease. For additional information and to learn more about the trial registration, please visit About OHB-607 OHB-607 is the recombinant form of human insulin-like growth factor-1 (IGF-1) complexed with its main binding protein (rhIGFBP-3). IGF-1 is a key driver of the growth and gestational development of vital organs, including the lung, eye, and brain. Mothers are the primary source of IGF-1 for the developing fetus until about 30 weeks gestational age, when the fetal liver takes over. As a result, infants born before 28 weeks of gestational age have low levels of IGF-1, which is believed to result in the failure of organs to grow and develop normally. A previous Phase 2a study demonstrated a decrease in severe BPD and the feasibility of OHB-607 infusion, supporting further investigation of OHB-607 for the prevention of complications of prematurity. About Bronchopulmonary Dysplasia (BPD) BPD is the most common complication of prematurity, resulting in chronic lung disease affecting 40-50% of infants born at less than 28 weeks of gestational age. BPD can lead to greater mortality, increased hospitalization, and cost burden, as well as long-term respiratory morbidity and neurodevelopment disability. SOURCE Chiesi Group

Phase 2License out/in

08 Feb 2024

·www.pharmaceutical-technology.com

BridgeBio and Kyowa Kirin partner for skeletal dysplasia treatment

Infigratinib will be developed to treat skeletal dysplasias. Credit: joel bubble ben / Shutterstock.com. BridgeBio Pharma has entered a strategic partnership with Kyowa Kirin , granting the latter an exclusive licence for the development and commercialisation of infigratinib in Japan. The collaboration, facilitated through BridgeBio affiliate QED Therapeutics, focuses on the treatment of achondroplasia, hypochondroplasia and other skeletal dysplasias. BridgeBio is eligible to receive $100m in upfront payment from Kyowa Kirin. BridgeBio is entitled to receive royalty payments on Japanese sales of infigratinib, potentially reaching the high 20 per cent range, along with further milestone-based payments. Infigratinib is an oral small molecule inhibitor targeting fibroblast growth factor receptor 3 (FGFR3), which plays a crucial role in skeletal dysplasias such as achondroplasia and hypochondroplasia. See Also: FDA accepts Bristol Myers Squibb’s sBLA for NSCLC treatment regimen Mecasermin rinfabate by Chiesi Farmaceutici for Bronchopulmonary Dysplasia: Likelihood of Approval By hindering FGFR3, infigratinib addresses these conditions at their source. BridgeBio made a significant advancement in December 2023 by dosing the first child in PROPEL 3, a Phase III pivotal trial. The one-year placebo-controlled trial is designed to evaluate the safety and efficacy of infigratinib in patients aged three to 18 with open growth plates and diagnosed with achondroplasia. The Phase III trial is a follow-up to the successful Phase II PROPEL 2 trial which showed promising results. Infigratinib demonstrated a significant increase in annualised height velocity of plus 3.38cm per year – the strongest clinical result reported so far. Kyowa Kirin plans to initiate discussions with Japan’s Pharmaceuticals and Medical Devices Agency in 2024. The goal is to begin a Japanese-registered trial of the drug by 2025. Kyowa Kirin Strategy Division head, vice-president, chief strategy officer and managing executive officer Yasuo Fujii stated: “It is important for us to strengthen our portfolio by introducing pipelines in the fields of bone and mineral disorders, including achondroplasia. “Based on the results from the latest clinical trials, we believe BridgeBio’s infigratinib has high potential for treating achondroplasia. “We will steadily advance the development in Japan and aim to deliver life-changing value to people with skeletal dysplasias including achondroplasia.” Last month, BridgeBio secured strategic financing of $1.25bn from Blue Owl Capital and the Canada Pension Plan Investment Board for genetic therapies.

Phase 3Clinical ResultLicense out/inPhase 2

24 Sep 2018

·www.globenewswire.com

Aton Reports New and Updated Intersections Including 65.3M @ 2.84 G/T Gold and 5.26% Zinc From Surface Channel Sampling at Rodruin

VANCOUVER, British Columbia, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Aton Resources Inc. (AAN: TSX-V) (“Aton” or the “Company") is pleased to provide investors with a further update on the channel sampling and drilling programmes at the Rodruin prospect at the Company’s 100% owned Abu Marawat Concession (“Abu Marawat” or the “Concession”), located in the Eastern Desert of Egypt. Highlights: Sampling of an extension to surface channel sample profile ROC-009 in the Aladdin’s Hill area at Rodruin (see news release dated August 23, 2018) has returned an overall and updated mineralised intersection of 65.3m @ 2.84 g/t Au and 5.26% Zn (previously reported as 39m @ 3.62 g/t Au and 5.44% Zn); New channel sample profile ROC-017 in the Spiral Pit area has returned a mineralised intersection of 50.3m @ 1.37 g/t Au and 0.56% Zn, confirming the presence of widespread mineralisation at surface in a previously untested area approximately 350-400m east-southeast of Aladdin’s Hill; The zone of mineralisation identified by channel and grab sampling on the South Ridge and in the Central Valley now extends over an area of approximately 600m x 200m, and over a vertical profile of at least 140m. Further high grade mineralisation has previously been sampled on the North Ridge, returning assay values of up to 321 g/t Au (see news releases dated February 6, 2018 and April 16, 2018). Drilling is currently testing the surface mineralisation on the South Ridge; The first 11 holes (ROP-001 to ROP-011) of the reverse circulation percussion (“RC”) drilling programme have been completed, with all holes intersecting mineralisation associated with gossanous carbonates and/or slates, and most intersecting ancient underground mine workings. Six batches of samples have been dispatched from site for analysis at ALS Minerals in Romania, with the first results still expected before the end of September 2018. “We are very pleased to report the continued expansion of the surface mineralised zone at Rodruin, with the extension of mineralisation in existing channel sample profiles, as well as significant assay results from a new channel profile some 350-400m away from Aladdin’s Hill and close to the high grade underground Spiral Pit workings” said Mark Campbell, President and CEO. “From these results, we are identifying extensions to, and analogues of the Aladdin’s Hill mineralisation, as well as possibly significant new gold-bearing mineralised zones around the Spiral Pit. Our current drilling program is uncovering the overall extent of the maze of ancient workings at Aladdin’s Hill. Many additional workings are distributed over both the South and North Ridges, demonstrating that Rodruin was a very significant mining centre in ancient times, giving us confidence in the overall potential of Rodruin. Drilling continues to intercept what is interpreted as being the mineralised package, and we look forward to releasing the first batch of drill results shortly.” Channel sampling at RodruinFurther results are now available from the surface channel sampling programme at Rodruin, which is testing mineralisation exposed in drill access road cuttings. To date 17 channel profiles have been sampled (ROC-002 to ROC-018), including 2 profiles close to the Spiral Pit underground workings (ROC-017 and ROC-018). The first 8 profiles ROC-002 to ROC-009 (see Figure 1) in the Aladdin’s Hill area were all mineralised with gold and zinc (see news releases dated August 7, 2018, August 23, 2018 and September 12, 2018), returning significant intersections including 62.6m @ 2.34 g/t Au (profile ROC-003) and 64.9m @ 2.29 34 g/t Au (profile ROC-005). Good mineralisation has also been returned from channel sample profile ROC-011 in the Central Valley, 400m to the east of Aladdin’s Hill, and 200m to the north of the Spiral Pit (see news release dated September 4, 2018). Further updates will be provided when additional assay results become available. Samples from the channel sampling programme were crushed to -4mm at the Company’s onsite sample preparation facility at Hamama, with c. 500g splits shipped to ALS Minerals at Rosia Montana, Romania for analysis. Samples were analysed for gold by fire assay using analytical code Au-AA23; and silver, copper, lead and zinc with an aqua regia digest followed by an atomic absorption spectroscopy finish (analytical code AA45). High grade gold samples (>10 g/t Au) were re-analysed using analytical code Au-AA25; and high grade Ag and base metal samples (Ag >100 g/t, and Cu, Pb, and Zn >10,000ppm or >1%) were routinely re-analysed using the ore grade technique AA46. For full details of sampling procedures please refer to the news release dated August 7, 2018. Figure 1: Schematic geological plan of the Aladdin’s Hill area, showing the location of drill access roads, drill pads and channel sample profiles (see Appendix A for intersection details) is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a91996ea-d083-49a2-ac8e-2d347cea581c Further assay results are now available from channel sample profile ROC-009, located approximately 130m northeast of the main ancient underground workings at Aladdin’s Hill (see Figure 1); and ROC-017, located near the ancient Spiral Pit underground workings approximately 350m east-southeast of Aladdin’s Hill (see Figure 2). Details of the mineralised intersections from these profiles are provided below in Table 1, and full details of all channel sample intersections to date are provided in Appendix A. Profile IDProfile length (m)Intersection (m)Au (g/t)Ag (g/t)Cu(%)Pb (%)Zn (%)CommentsFromToIntervalROC-00977.30.065.365.32.843.60.300.065.26Previously reported as 39m @ 3.62 g/t Au and 5.44% Zn1ROC-017108.358.0108.350.31.377.40.100.010.56Spiral Pit area incl.58.082.024.02.275.60.190.010.67incl.88.5101.613.10.7011.00.020.020.43incl.106.1108.32.20.743.30.010.010.13Notes: See news release dated August 23, 2018Intersections calculated using a cutoff grade of 0.5 g/t Au Table 1: Mineralised intersections from channel sample profiles ROC-009 and ROC-017 Figure 2: Schematic geological plan of the Spiral Pit area, showing the location of drill access roads and channel sample profiles is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3c3f4881-97a1-4427-8aed-252fe09db969 Profile ROC-009 returned an initial mineralised intersection of 39.0m @ 3.62 g/t Au and 5.44% Zn (see news release dated August 23, 2018) over its entire sampled length. The profile was subsequently extended to the north, with further mineralisation being returned over an additional 26.3m length, associated with gossanous and sheared carbonate rocks and altered and weathered slates. The profile has now returned an overall mineralised intersection of 65.3m @ 2.84 g/t Au and 5.26% Zn. The mineralisation at the southeastern end of this profile was terminated by cemented scree and talus cover (see Figure 1), with potential for the mineralisation to extend beneath this cover. Further mineralisation has been exposed in a new drill access road located between profile ROC-009, and profiles ROC-003 (62.6m @ 2.34 g/t Au) and ROC-004 (25.5m @ 4.74 g/t Au), and this will be sampled as soon as possible (see Figures 1 and 3). Channel sample profile ROC-017 was completed on the “southside high road” just to the south of the ancient Spiral Pit underground workings, from which selective grab samples have returned grades of up to 35.3 g/t Au and 37.9% Zn (see Figure 2). Sampling was carried out in a sequence of slates and greywackes in the immediate footwall of the South Ridge Thrust (see news release dated September 12, 2018), which is overlain by massive carbonate which caps the South Ridge in this area. The Spiral Pit is also located in the immediate footwall of the South Ridge Thrust. Profile ROC-017 returned a mineralised intersection of 50.3m @ 1.37 g/t Au and 0.56% Zn, from a fault-bounded block of altered, weathered and gossanous slates and greywackes. The north-south trending fault which controls the western extent of the sampled mineralisation runs directly into the Spiral Pit workings. Mineralisation in this area is structurally controlled, is located in the footwall block of the South Ridge Thrust, and appears broadly similar to that seen in the Aladdin’s Hill area, some 400m to the west-northwest. Assays remain pending from profile ROC-018 east of the Spiral Pit (see Figure 2), and work is currently being undertaken to widen the southside high road to allow access for the drilling rig to drill test this area. Additionally a new access road is being pushed along the northern side of the South Ridge to provide access to further fault-bounded mineralisation, ancient workings and tailings associated with gossanous carbonates which outcrop high on the Central Buttress of the South Ridge (see Figures 2 and 3). Assays of up to 9.59 g/t Au from selective grab samples (sample AHA-18804, see news release dated February 6, 2016) have been returned from this area. Further channel sampling of access roads in this area will also be undertaken as soon as possible. RC drilling programme Figure 3: Drilling at Aladdin’s Hill, viewed from the northwest. Channel sample profile ROC-009 is located on the north flank of the South Ridge, along the lower drill access road, as marked is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d00d9267-b718-4daa-af26-ed4ff8181155 The Phase 1 RC drilling programme is now well underway at Rodruin, and to date 11 drill holes have been completed, ROP-001 to ROP-011, in the immediate Aladdin’s Hill area (see Figure 3). All holes have intersected mineralisation, associated with gossanous carbonate rocks and altered slates. Significantly almost all holes completed to date have also intersected ancient underground workings at depths of up to 40m below ground level. Several holes have had to be abandoned due to them intersecting significant and large underground workings. Assay results from the first 3 holes, ROP-001 to ROP-003, are expected by the end of September. RodruinThe Rodruin prospect was discovered in December 2017 by Aton geologists (see news release dated December 14, 2017), and is located approximately 18km east of the Company’s Hamama West mineral deposit (see Figure 4). Field mapping and sampling has indicated the presence of ancient mine workings and extensive gold mineralisation over an area of at least 700m x 400m at surface. Abundant visible gold has been identified in hand specimens from surface outcrops, and ancient dumps and underground workings, with individual selective grab samples assaying up to 321 g/t Au. The main series of extensive ancient underground workings in the Aladdin’s Hill area has also been sampled to a depth of approximately 40m below ground level, indicating continuation of the surface mineralisation at depth (see news releases dated February 6, 2018, March 5, 2018 and April 16, 2018). Underground workings at the Spiral Pit have been sampled to a depth of 12-15m below ground level (see news release dated August 7, 2018). Figure 4: Abu Marawat regional geology, showing the location of the Rodruin prospect is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/21d20549-408c-4d9c-af9f-7169b7b15792 Construction of drill access roads and pads is ongoing at Rodruin to support the current Phase 1 RC drilling programme, including the construction of further drill access roads to access additional mineralised zones at Rodruin, away from the immediate Aladdin’s Hill area. The Phase 1 RC programme is planned to consist of approximately 4,000 to 6,000 metres of RC drilling, and will initially test the main zone of ancient workings and mapped mineralisation in the Aladdin’s Hill area, and is expected to take about 6 weeks to complete. Samples from all 11 drill holes completed to date have already been dispatched from site, and the first assay results are still expected before the end of September 2018. About Aton Resources Inc.Aton Resources Inc. (AAN: TSX-V) is focused on its 100% owned Abu Marawat Concession (“Abu Marawat”), located in Egypt’s Arabian-Nubian Shield, approximately 200km north of Centamin’s Sukari gold mine. Aton has identified a 40km long gold mineralised trend at Abu Marawat, anchored by the Hamama deposit in the west and the Abu Marawat deposit in the east, containing numerous gold exploration targets, including three historic British mines. Aton has identified several distinct geological trends within Abu Marawat, which display potential for the development of RIRG and orogenic gold mineralisation, VMS precious and base metal mineralisation, and epithermal-IOCG precious and base metal mineralisation. Abu Marawat is over 738km2 in size and is located in an area of excellent infrastructure; a four-lane highway, a 220kV power line, and a water pipeline are in close proximity. Qualified PersonThe technical information contained in this News Release was prepared by Javier Orduña BSc (hons), MSc, MCSM, DIC, MAIG, SEG(M), FGS, Exploration Manager of Aton Resources Inc. Mr. Orduña is a qualified person (QP) under National Instrument 43-101 Standards of Disclosure for Mineral Projects. For further information regarding Aton Resources Inc., please visit us at www.atonresources.com or contact: Mark CampbellPresident and Chief Executive Officer Tel: +202-27356548Email: mcampbell@atonresources.com Note Regarding Forward-Looking StatementsSome of the statements contained in this release are forward-looking statements. Since forward-looking statements address future events and conditions; by their very nature they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Appendix A – Details of Rodruin channel sample profile intersections ProfileIDProfile length(m)Intersection (m)Au (g/t)Ag (g/t)Cu(%)Pb (%)Zn (%)CommentsFromToIntervalROC-00110.70.010.710.75.555.30.040.010.41Chip channel profile from Phase 1 sampling (December 2017)ROC-00248.60.048.648.62.123.90.100.020.91Previously reported as 23.5m @ 1.99 g/t Au2incl.0.023.523.51.995.40.150.021.55incl.32.948.615.73.393.00.060.020.29ROC-00398.40.062.662.62.342.20.070.021.49Previously reported as 31.5m @ 1.49 g/t Au2ROC-00428.50.025.525.54.748.20.070.000.64 ROC-00570.90.064.964.92.292.70.110.060.21Previously reported as 28.0m @ 1.83 g/t Au2 incl.0.03.53.50.642.90.010.000.30incl.7.764.957.22.492.40.130.060.16ROC-00637.020.537.016.52.153.00.040.020.55 ROC-0077.03.07.04.04.343.60.050.061.65Now superseded by extended ROC-008 profileROC-00846.010.046.036.02.093.80.040.050.65Previously reported as 17.5m @ 2.09 g/t Au2ROC-00977.30.065.365.32.843.60.300.065.26Previously reported as 39m @ 3.62 g/t Au and 5.44% Zn1ROC-01033.0--------Sub-grade: 33m @ 0.12 g/t Au and 0.38% Zn, Central Valley areaROC-01156.611.013.02.00.571.40.020.020.29Central Valley area34.856.621.81.172.60.010.020.11ROC-01224.10.013.013.01.413.70.180.014.58South of Aladdin’s Hill ROC-01383.09.014.75.71.320.60.010.000.04Profile extended - all assays pending except 9.0-14.7mROC-01427.221.124.93.81.121.00.010.000.03South Ridge ThrustROC-0154.0--------NSA > 0.22 g/t AuROC-0164.0--------Unmineralised, NSA > 0.01 g/t AuROC-017108.358.0108.350.31.377.40.100.010.56Spiral Pit area incl.58.082.024.02.275.60.190.010.67incl.88.5101.613.10.7011.00.020.020.43incl.106.1108.32.20.743.30.010.010.13ROC-018 Spiral Pit area – assays pendingNotes: See news release dated August 23, 2018See news release dated September 12, 2018Intersections calculated using a cutoff grade of 0.5 g/t Au

AHA

100 Deals associated with Mecasermin Rinfabate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Mecasermin Rinfabate	H01AC05	DB14751

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Growth Disorders	US	Insmed, Inc.	12 Dec 2005
IGFD	US	Insmed, Inc.	12 Dec 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Laron Syndrome	Phase 3	US	Insmed, Inc.	-
Laron Syndrome	Phase 3	CN	Insmed, Inc.	-
Laron Syndrome	Phase 3	AR	Insmed, Inc.	-
Laron Syndrome	Phase 3	AU	Insmed, Inc.	-
Laron Syndrome	Phase 3	BR	Insmed, Inc.	-
Laron Syndrome	Phase 3	EG	Insmed, Inc.	-
Laron Syndrome	Phase 3	DE	Insmed, Inc.	-
Laron Syndrome	Phase 3	IL	Insmed, Inc.	-
Laron Syndrome	Phase 3	IT	Insmed, Inc.	-
Laron Syndrome	Phase 3	NO	Insmed, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00577577 (CTgov)	Phase 2	Myotonic Dystrophy	69	placebo	yvnnsvqgdj(rcyttvbawb) = fagkaowoac bfdxyxweek (cloecdnufq, osxuikugls - ndbqjnmzpu) View more	-	06 Jan 2022
NCT01096784 (Pubmed) Manual	Phase 2	Retinopathy of Prematurity	121	Mecasermin Rinfabate Recombinant	pifvuzxbph(ebammiudpq) = did not decrease cslgkncbgs (wiqthirxuf ) View more	Negative	01 Mar 2019
				standard neonatal care
ERS2017	Phase 2	Bronchopulmonary Dysplasia	121	rhIGF-1/rhIGFBP-3	aibtazlava(rimiboehzs) = clveeptsfj rwmhtbwanf (dnobieerpe )	-	01 Sep 2017
				Recombinant human (rh)IGF-1/rhIGFBP-3	aibtazlava(rimiboehzs) = ufpsgfhouh rwmhtbwanf (dnobieerpe )
NCT01096784 (PipelineReview) Manual	Phase 2	-	121	SHP607	nduhddqheo(yrtbppykbl) = psdgcpnpbe ufkbjxnkqm (qhmuxuhaoz ) View more	Positive	30 Jun 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis